Scienture Holdings Inc's Business Segments

The registrant is a clinical-stage biopharmaceutical company with a limited operating history. Its business focuses on the development of pharmaceutical product candidates, a process that is lengthy, costly, and uncertain. Due to limited resources and the need to secure capital, the company prioritizes certain product candidates, which may affect the development of other candidates. The company's success depends on completing clinical development, obtaining regulatory approvals, and commercializing its product candidates. It may seek collaborations with third parties to support product development, though such collaborations may not be secured on commercially acceptable terms. The registrant is subject to federal and state healthcare laws, fraud and abuse laws, false claims laws, health data privacy and security regulations, and other regulatory requirements. Non-compliance with these laws could result in investigations and significant penalties. Even after regulatory approval, the company will face ongoing regulatory obligations that may impose substantial costs. The company also faces risks related to the need for additional capital, potential stockholder dilution, and challenges in managing growth and regulatory compliance, which could materially affect its business and results of operations.

As of December 31, 2025, the Company operates a single reportable and operating segment within the United States. The co-Chief Executive Officers serve as the chief operating decision-makers, making resource allocation decisions and assessing performance based on aggregate financial information. There are no segment managers responsible for planning, strategy, or key operational decisions. Key financial measures reviewed include total revenues, gross profit, total operating expenses (including research and development expenses), and net loss from continuing operations. Significant expenses reported to the chief operating decision-makers include research and development costs for SCN-102, SCN-104, SCN-106, and SCN-107, wage and salary expenses, professional fees, accounting and legal expenses, and non-cash impairment losses. Additional expenses comprise technology costs, general and administrative expenses (including stock-based compensation), and depreciation and amortization.